专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011074743A1 GRANULES COMPRISING FENOFIBRATE ADSORBED ON CARRIER SURFACE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：包含在载体表面上吸收的复合物的颗粒和包含其的药物组合物
公开(公告)号：WO2011074743A1
公开(公告)日：2011-06-23
申请号：PCT/KR2010/001713
申请日：2010-03-19
申请人： SAMIL PHARMACEUTICAL CO., LTD. , PARK, Young-Joon , CHO, Young-Dae
发明人： PARK, Young-Joon , CHO, Young-Dae
IPC分类号： A61K9/16 , A61K9/20 , A61K31/216 , A61K9/48
CPC分类号： A61K31/216 , A61K9/1652 , A61K9/205 , A61K9/2054
摘要： The present invention provides a granule obtained by adsorbing and drying an aqueous suspension comprising fenofibrate, a suspending agent, and a bile acid or its salt on a carrier surface; and a pharmaceutical composition comprising the same. Since the granules according to the present invention does not require using an organic solvent, environmental problems such as environmental contamination and/or problems related to a potential residual solvent can be avoided. In particular, since a tablet formulated using the granule according to the present invention has high bioavailability and is hardly affected by food, a stable in-vivo behavior may be expected regardless of food intake.
摘要翻译：本发明提供一种颗粒，其通过在载体表面上吸附并干燥包含非诺贝特，悬浮剂和胆汁酸或其盐的水性悬浮液而获得; 和含有该组合物的药物组合物。由于根据本发明的颗粒不需要使用有机溶剂，因此可以避免诸如环境污染和/或与潜在的残留溶剂有关的问题等环境问题。特别是，由于使用本发明的颗粒配制的片剂具有高的生物利用度并且几乎不受食物的影响，所以可以预期稳定的体内行为，而与食物摄取无关。

2. 发明申请

WO2010071313A3 GRANULES CONTAINING LACIDIPINE, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME 审中-公开
标题翻译：含有镧系元素的颗粒以及包含其的药物组合物
公开(公告)号：WO2010071313A3
公开(公告)日：2010-10-07
申请号：PCT/KR2009007212
申请日：2009-12-04
申请人： SAMIL PHARMACEUTICAL CO LTD , PARK YOUNG-JOON , JEONG EUN-KYUNG
发明人： PARK YOUNG-JOON , JEONG EUN-KYUNG
IPC分类号： A61K9/16 , A61K31/44
CPC分类号： A61K31/44 , A61K9/2081 , A61K9/5026 , A61K9/5078
摘要： The present invention relates to granules containing lacidipine wherein a mixture of lacidipine, surfactant, and polyvinylpyrrolidone is coated on the surfaces of particles of water-soluble saccharides, and to pharmaceutical compositions comprising same. The lacidipine-containing granules according to the present invention exhibit a superior dissolution rate and solubility in an aqueous medium, and thus improve bioavailability. Specifically, solid preparations such as tablets or the like obtained from the lacidipine-containing granules of the present invention exhibit an improved cumulative dissolution rate within 30 minutes, which is two times faster than conventional preparations, leading to quick pharmacological activity and excellent bioavailability.
摘要翻译：本发明涉及含有拉西地平的颗粒及其包含拉西地平，表面活性剂和聚乙烯吡咯烷酮的混合物的水溶性糖颗粒表面上的包衣，以及包含其的药物组合物。根据本发明的含拉西地平的颗粒在水性介质中表现出优异的溶解速率和溶解度，并因此提高生物利用度。具体而言，从本发明的含有拉西地平的颗粒获得的固体制剂如片剂等在30分钟内表现出改善的累积溶出速率，其比常规制剂快两倍，从而导致快速的药理活性和优异的生物利用度。

3. 发明申请

WO2010147309A3 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY GASTROINTESTINAL DISEASE COMPRISING PATCHOULI EXTRACT 审中-公开
标题翻译：用于预防或治疗包含PATCHOULI提取物的炎症胃肠疾病的药物组合物
公开(公告)号：WO2010147309A3
公开(公告)日：2011-04-21
申请号：PCT/KR2010003150
申请日：2010-05-19
申请人： SAMIL PHARMACEUTICAL CO LTD , PARK YOUNG-JOON , PARK BYUNG-CHUL , KIM SUN-YEOU , KIM JUNG-AE
发明人： PARK YOUNG-JOON , PARK BYUNG-CHUL , KIM SUN-YEOU , KIM JUNG-AE
IPC分类号： A61K36/53 , A61K36/428 , A61P1/00 , A61P1/04
CPC分类号： A61K36/53
摘要： The present invention provides a pharmaceutical composition for preventing or treating inflammatory gastrointestinal disease, and in particular a pharmaceutical composition for preventing or treating ulcerative colitis, Crohn's disease, irritable bowel syndrome or gastritis, which comprises patchouli (Pogostemon cablin) extract as an active ingredient. The patchouli extract has a prophylactic and therapeutic action against ulcerative colitis or Crohn's disease which are commonly known as inflammatory bowel disease, as it effectively suppresses inflammatory bowel disease induced by trinitrobenzene sulfonic acid (TNBS) and also reduces MPO (myeloperoxidase) activity. Further, the patchouli extract not only has a prophylactic and therapeutic action against irritable bowel syndrome because it suppresses contraction of small-intestine and large-intestine circular muscle, but it also has a prophylactic and therapeutic action against gastritis because it has a protective action (cytoprotective action) in damaged gastric mucosa.
摘要翻译：本发明提供一种预防或治疗炎性肠胃疾病的药物组合物，特别是用于预防或治疗溃疡性结肠炎，克罗恩病，肠易激综合征或胃炎的药物组合物，其包含广藿香（Pogostemon cablin）提取物作为活性成分。广藿香提取物具有针对溃疡性结肠炎或克罗恩病的预防和治疗作用，其通常称为炎症性肠病，因为其有效抑制由三硝基苯磺酸（TNBS）诱导的炎症性肠病，并且还降低MPO（髓过氧化物酶）活性。此外，广藿香提取物不仅具有针对肠易激综合征的预防和治疗作用，因为它抑制小肠和大肠环状肌的收缩，而且由于具有保护作用，因此也具有预防和治疗胃炎的作用细胞保护作用）在受损的胃粘膜中。

4. 发明申请

WO2010067986A3 COMPOSITION FOR CONTROLLING GASTROINTESTINAL TRACT MOVEMENT 审中-公开
标题翻译：用于控制胃肠道运动的组合物
公开(公告)号：WO2010067986A3
公开(公告)日：2010-09-10
申请号：PCT/KR2009007215
申请日：2009-12-04
申请人： SAMIL PHARMACEUTICAL CO LTD , PARK YOUNG JOON , CHO KWAN-HYUNG , CHOI YONG-KYU
发明人： PARK YOUNG JOON , CHO KWAN-HYUNG , CHOI YONG-KYU
IPC分类号： A61K31/24 , A61P1/00
CPC分类号： A61K31/24
摘要： The present invention provides a novel composite composition for controlling gastrointestinal tract movement comprising an enkephaline receptor agonist and a prokinetic agent. The composite composition provided according to the present invention is a general purpose composite composition for controlling movement of the upper and lower gastrointestinal tracts that enables improved movement controlling capabilities of the upper and lower gastrointestinal tracts in a complementary fashion, based on mutually different mechanisms of an enkephaline receptor agonist and a prokinetic agent. Thus, this is a novel composite composition that exhibits inclusive and effective therapeutic actions on various diseases including functional gastrointestinal disturbance, constipation, and irritable bowel syndrome as well as diabetic intestinal motility disorder, intestinal motility disorder caused by chemotherapy, ileus caused by intestinal motility disorder, and intestinal motility disorder in myotonic dystrophy patients.
摘要翻译：本发明提供了一种用于控制胃肠道运动的新型复合组合物，其包含脑啡肽受体激动剂和促动力剂。根据本发明提供的复合组合物是用于控制上消化道和下消化道的运动的通用复合组合物，其能够以互补的方式改善上胃肠道和下胃肠道的运动控制能力，基于相互不同的机制脑啡肽受体激动剂和促动力剂。因此，这是一种新型复合组合物，其对各种疾病包括功能性胃肠道紊乱，便秘和肠易激综合征以及糖尿病肠蠕动障碍，由化学引起的肠蠕动障碍，肠蠕动紊乱引起的肠梗阻，以及强直性营养不良患者的肠蠕动障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式